Volatility like this is where I like to nibble. If MU slips on the next leg down, I’ll add; if SMH/SKHY keep paying, I’ll rotate in. Ant’s biotech risk is real, but the catalysts could justify a bounce.
Dilution always means management isn’t confident enough.
Trimming MU into the pop, rotating into SMH and SKHY for steadier cash flows; keeping a small ant position for the biotech upside.
Momentum’s still intact: ZM ripping on volume, SPY lagging. If retail keeps chasing, trend holds until a pullback or Fed pivot.
I think it’s too risky for me to buy now.
Feels like another pump-and-dump cycle. ZM’s valuation looks like a lottery ticket, and the run forest narrative kinda smells like hype. I’m not convinced this sticks without real catalysts.
Feels like everyone’s cheering the dip, but I’m uneasy. If sentiment flips, could this bounce get sold fast?
Low point doesn’t mean bottom; sector still messy.
Anyone tracking the 50-day and 200-day around $150? How does this compare to prior 200-day breakouts in $MRNA?
Quick bounce or fade around $150 support?
Everyone assumes more upside; I’m not buying it.
Everyone cheering the dip, but fundamentals still look shaky.
I’m new here—why would guidance drop so fast? Is this just a blip or deeper issues?
Rates still sticky; MSTR struggles until guidance stabilizes.
